Axicabtagene Ciloleucel + Brexucabtagene Autoleucel + Anitocabtagene autleucel + KITE-753 + KITE-197 + KITE-363
Pre-clinicalRecruiting 0 watching 0 views this week💤 Quiet
22
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Solid and Hematological Malignancies
Conditions
Solid and Hematological Malignancies
Trial Timeline
Dec 15, 2021 → Dec 1, 2040
NCT ID
NCT05041309About Axicabtagene Ciloleucel + Brexucabtagene Autoleucel + Anitocabtagene autleucel + KITE-753 + KITE-197 + KITE-363
Axicabtagene Ciloleucel + Brexucabtagene Autoleucel + Anitocabtagene autleucel + KITE-753 + KITE-197 + KITE-363 is a pre-clinical stage product being developed by Gilead Sciences for Solid and Hematological Malignancies. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05041309. Target conditions include Solid and Hematological Malignancies.
Hype Score Breakdown
Clinical
5
Activity
2
Company
9
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05041309 | Pre-clinical | Recruiting |
Competing Products
20 competing products in Solid and Hematological Malignancies